Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PB1023 Injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

NCT01478399
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PB1023 Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

NCT01236404
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

NCT01427257
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Single Dose PB1023
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 28, 2026, 7:58 PM EDT